Skip to main content
. 2009 May;11(5):436–447. doi: 10.1593/neo.09208

Figure 7.

Figure 7

Neither docetaxel nor vincristine triggers activation of the UPR in melanoma cells. (A) Mel-RM and MM200 cells with or without treatment with TM (3 µM), docetaxel (20 nM), or vincristine (50 ng/ml) for indicated periods were subjected to Western blot analysis. (B) Mel-RM and MM200 cells with or without treatment with TM (3 µM), docetaxel (20 nM), or vincristine (50 ng/ml) for 16 hours. Reverse transcription-polymerase chain reaction products of XBP1 mRNA were digested with Apa-LI for 90 minutes followed by electrophoresis. (C) Melanoma cells were treated with TM (3 µM), docetaxel (20 nM), or vincristine (50 ng/ml) for 16 hours. Whole cell lysates were subjected to Western blot analysis. The data shown are representative of three individual experiments.

HHS Vulnerability Disclosure